CLINICAL PHARMACOLOGICAL APPROACH TO THE USE OF DRUGS AFFECTING HEMOSTASIS IN CHILDREN
Keywords:
Bleeding, prothrombin complex concentrates, recombinant activated factor VIIAbstract
The paper examines the safety and efficacy of using a domestic hemostatic agent, recombinant activated factor VII, coagulagil VII, and prothrombin complex concentrate, prothromplex-600 (Baxter, Austria), in neonatal and pediatric cardiac surgery. The study included 56 children aged 7 days to 5.5 years, who underwent artificial circulation surgery for congenital heart defects. Clinical and laboratory data indicate that coagulagil VII and prothromplex-600 are effective in stopping bleeding.
References
Chuprova AV The neonatal hemostasis system
in norm and pathology (scientific review).
Bulletin of the Siberian Branch of the Russian
Academy of Medical Sciences. 2015; 4: 13–9.
Shabalov NP, Ivanov DO, Shabalova NN
Hemostasis in the dynamics of the first week of
life as a reflection of the mechanisms of
adaptation to extrauterine life of the newborn.
Pediatrics. 2020; 3: 84–91.
Kotova AN, Tumanyan MR, Samsonova NN
Hemostasis system - definition, dynamics of
age-related changes and features in infants
with cyanotic congenital heart defects.
Childhood diseases of the heart and blood
vessels. 2010; 3: 17–9.
Samsonova N.N., Kozar E.F., Plyushch M.G.,
Klimovich L.G., Samuilova D.Sh. Characteristics
of the hemostasis system in cardiac surgery
patients of the first year of life with congenital
heart defects. Children's diseases of the heart
and blood vessels. 2015; 4: 54–8.5. Barkagan L.Z. Hemostasis disorders in children.
Moscow; 2013
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
